TMCnet News
High R&D Expenditure Will Positively Impact the Global Acquired Orphan Blood Diseases Therapeutics Market through 2019: TechNavioHigh expenditure on R&D has boosted the growth of the Global Acquired Orphan Blood Diseases Therapeutics Market, which is expected to post a CAGR of 12.29 percent from 2014-2019, says research firm TechNavio. About the Report According to the new report by TechNavio, the high therapeutic value of orphan blood disease drugs combined with the limited patient population have motivated pharmaceutical companies to increase the price of the drugs. "A 2013 research study conducted in the UK reported that about two-thirds of the members of parliament agreed that there should be no price cap on orphan drugs," says Faisal Ghaus, Vice President of TechNavio. The TechNavio report indicates that untapped markets in many geographical locations will provide immense opportunities for vendors to invest over the projected period. Big players in the market who concentrate on the development of drugs for acquired orphan blood diseases are targeting physicians who are able to prescribe these drugs in place of more invasive surgeries and chemotherapy. This helps manufacturers to increase their product price. "Soliris, manufactured by Alexion Pharmaceuticals,is the only drug available for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and also carries the title of the most expensive drug in the world," says Ghaus. Key Information Covered in the Report:
TechNavio currently has more than 3000 market research reports on a huge range of topics, including 100+ reports on the therapeutics market:
If you are interested in more information, please contact our media team at [email protected].
|
